Van E. Haynie

Alamo Rent-A-Car LLC provides passenger car rental services. It offers cars, convertibles, SUVs and minivans. The company was founded in 1974 and is headquartered in St. Louis, MO.

Dancing Bear Investments provides investment services. The private company is based in Fort Lauderdale, FL.

Boca Resorts LLC owns and operates resorts and hotels. The company is headquartered in Boca Raton, FL.

Kalyra Pharmaceuticals, Inc. manufactures small molecule drugs. The company was founded by Brian T. Dorsey, Cam L. Garner and Kevin Bunker and is headquartered in San Diego, CA.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Part of Registry Management Co. LLC, Tralliance Corp. is the registry for the .travel sponsored top level domain name (stld). The company is based in New York, NY. Tralliance aims to serve the travel and tourism community by developing products and services that promote the efficiencies and convenience of e-commerce for all bona fide travel companies and tourism organizations on the internet. The .travel stld is designed to improve internet identity, create advanced distribution channels, and establish a stronger level of trust between the industry and its customers. Tralliance offers a thick registry, improved "whois data," and a review process that includes provision for resolution of eligibility and name selection denial issues, supplementing the ICANN dispute resolution policies. Tralliance was acquired by Registry Management Co. LLC from theglobe.com, Inc. on September 29, 2008 for $7.71 million.

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

CardioCreate, Inc. develops cardiac stem cell therapies. Its stem cell therapies are used to repair and replace damaged heart tissues after a heart attack. The company was founded by Ned Israelsen, Stephen F. Flaim and Mark A. Sussman and is headquartered in San Diego, CA.

Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA.

Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY.

Energy Exploration Technologies, Inc. is a clean energy technology company that aims to power the future by building disruptive technologies to support the necessary shift to clean energy. The company is based in Fort Lauderdale, FL, and has partnered with Membrane Technology and Research, Inc. and other top labs. EnergyX has developed a suite of direct lithium extraction technologies that can treat any brine type and is building next-generation lithium batteries with its proprietary technology, Solis, focused on solid-state lithium-ion batteries. The company was founded in 2018 by entrepreneur Teague Egan and a team of leading scientists and sustainable energy veterans. Teague Egan has been the CEO since 2017.

Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation.